Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Heron Therapeutics (HRTX) Accumulated Depreciation & Amortization (2016 - 2025)

Heron Therapeutics' Accumulated Depreciation & Amortization history spans 12 years, with the latest figure at $12.9 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 27.83% year-over-year to $12.9 million; the TTM value through Dec 2025 reached $12.9 million, down 27.83%, while the annual FY2025 figure was $12.9 million, 27.83% down from the prior year.
  • Accumulated Depreciation & Amortization reached $12.9 million in Q4 2025 per HRTX's latest filing, down from $17.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $17.8 million in Q4 2024 to a low of $12.9 million in Q4 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $15.1 million, with a median of $14.3 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: rose 21.81% in 2021, then dropped 27.83% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $13.2 million in 2021, then increased by 7.93% to $14.3 million in 2022, then rose by 19.14% to $17.0 million in 2023, then increased by 4.81% to $17.8 million in 2024, then decreased by 27.83% to $12.9 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Accumulated Depreciation & Amortization are $12.9 million (Q4 2025), $17.8 million (Q4 2024), and $17.0 million (Q4 2023).